Common Contracts

1 similar null contracts

Licensing agreement for CRISPR-Cas9 genome-editing patents
July 5th, 2024
  • Filed
    July 5th, 2024

Bayer and ERS signed a patent license agreement whereby Bayer gains access to ERS' CRISPR-Cas9 genome-editing patents for certain cross-divisional applications in Bayer's core strategic areas.

AutoNDA by SimpleDocs
Time is Money Join Law Insider Premium to draft better contracts faster.